Skip to main content

Oregon State Flag An official website of the State of Oregon »

Oregon.gov Homepage

Frequently asked questions (FAQs)


  • The board conducts affordability reviews on prescription drugs and insulin products based on criteria in OAR 925.200.0010 and OAR 925.200.0020. The board will identify nine drugs and at least one insulin product that it determines may create affordability challenges for health care systems or high out-of-pocket costs for Oregonians. The board presents the list to the Oregon Legislature each year. This board process is outlined in Senate Bill 844, the board's founding legislation. Find prescription drug review dates and reports on the PDAB affordability review web page. 

  • The board is developing a plan for establishing upper payment limits on drugs sold in this state that are subject to affordability reviews under ORS 646A.694. As part of the study, the board will hold community forums across the state in 2024 seeking feedback from people about the high cost of prescription drugs in Oregon. The board direction for the study of upper payment limits is outlined in Senate Bill 192 (2023).​

  • The board provides policy recommendations, reports and letters for the Oregon Legislature. Each December, the board provides legislative policy recommendations for making prescription drugs more affordable. The board also provides a legislative report about generic drugs. Read the board 2023 policy recommendations, generic drug report and all other reports posted on the PDAB Legislative reports page.

  • The board approved policies to guide its work when it was first established in June 2022. Each year, the board reviews the policies and amends them, if needed. The board may adopt rules in accordance with applicable provisions under ORS Chapter 183. During the rulemaking process the public is encouraged to submit comments to provide feedback by signing up for and attending board meetings and hearings. Find all the policies and rules on the PDAB policies and rulemaking page. Additional information on the rules advisory committee schedules are posted on the PDAB RAC webpage.

  • The Prescription Drug Affordability Board is established in the Department of Consumer and Business Services under ORS 646A.693 to protect residents of Oregon, state and local governments, commercial health plans, health care providers, pharmacies licensed in Oregon and others within the health care system in this state from the high costs of prescription drugs. 

No.

  • ​Board meetings are virtual and take place on Wednesdays using Zoom for Government. View the board meeting schedule here. Register in advance for board meetings by clicking on the registration link next to each board meeting date. Meetings notices and other information will be posted on this web page and emailed out twice a month, two weeks and one week before the meeting. To receive notice of the board meetings, please sign up here.

  • Meeting videos are posted soon after each meeting. Meeting minutes are posted online after the board approves them. ​
​

  • ​​You will receive a confirmation email from Zoom after you register for the board meeting. If you have not received a confirmation email, try again to register by clicking on the Zoom registration link on the board calendar page. If you still have not received confirmation, please let us know so we can confirm your registration. Contact us at pdab@dcbs.oregon.gov.​

There are three ways to communicate with the board.
 
Oral testimony
For oral comments, please submit the PDAB public comment form no later than 24 hours before the PDAB meeting. The form is located on the Prescription Drug Affordability Board public comment page.

General written testimony
For written comments, please submit the PDAB public comment form with attachments no later than 72 hours before the PDAB meeting. The form is located on the Prescription Drug Affordability Board public comment page. Written comments will be posted to the PDAB website.

Public comment for drug affordability review
For written comments specific to drugs under review by the board, please submit the PDAB public comment form with attachments by the deadline listed on the public comment page. For oral testimony about drugs under review by the board, please submit the PDAB public comment form no later than 24 hours before the PDAB meeting. The form is located on the Prescription Drug Affordability Board public comment page. Written comments received by the deadline will be included in the board meeting materials and posted to the web.​


  • ​​General public comments submitted to the board can be about a variety of topics. The deadline for written comments is 72 hours before the meeting. The deadline for oral comments is 24 hours before the meeting. Comments submitted for the affordability review are specific to prescription drugs under review by the board and have different deadlines. For the 2024 deadlines for affordability review comments, see the table on the public comment form.